Compare · CNC vs TLSI
CNC vs TLSI
Side-by-side comparison of Centene Corporation (CNC) and TriSalus Life Sciences Inc. (TLSI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNC and TLSI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.69B, about 159.4x TLSI ($205.1M).
- Over the past year, CNC is up 15.9% and TLSI is down 37.5% - CNC leads by 53.4 points.
- TLSI has been more active in the news (8 items in the past 4 weeks vs 6 for CNC).
- CNC has more recent analyst coverage (25 ratings vs 6 for TLSI).
- Company
- Centene Corporation
- TriSalus Life Sciences Inc.
- Price
- $64.34-2.77%
- $3.46+3.59%
- Market cap
- $32.69B
- $205.1M
- 1M return
- +14.19%
- -23.96%
- 1Y return
- +15.90%
- -37.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 6
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest CNC
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 3,992 shares, increasing direct ownership by 19% to 24,748 units (SEC Form 4)
- Director Ford Monte E was granted 3,992 shares, increasing direct ownership by 37% to 14,827 units (SEC Form 4)
Latest TLSI
- TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by TriSalus Life Sciences Inc.
- Chief Commercial Officer Marshak Richard sold $1,450 worth of shares (543 units at $2.67), decreasing direct ownership by 0.43% to 125,101 units (SEC Form 4) to cover withholding tax
- Director Wahlstrom Mats bought $151,800 worth of shares (60,000 units at $2.53), increasing direct ownership by 69% to 147,555 units (SEC Form 4)
- Director Stansky Michael P bought $1,525,000 worth of shares (610,000 units at $2.50), increasing direct ownership by 49% to 1,240,722 units (SEC Form 4)
- Chief Financial Officer Patience David bought $17,253 worth of shares (7,100 units at $2.43), increasing direct ownership by 3% to 275,757 units (SEC Form 4)
- CEO and President Szela Mary T bought $102,776 worth of shares (39,682 units at $2.59), increasing direct ownership by 4% to 1,065,215 units (SEC Form 4) to cover withholding tax
- Director Gordon Gary B. bought $24,600 worth of shares (10,000 units at $2.46), increasing direct ownership by 16% to 72,510 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by TriSalus Life Sciences Inc.
- Director Gordon Gary B. was granted 52,754 shares, increasing direct ownership by 541% to 62,510 units (SEC Form 4)